Are increased cerebrospinal fluid and serum levels of S100B in first-onset schizophrenia related to a degenerative release of glial fibrillar acidic protein , myelin basic protein and neurone-specific enolase from glia or neurones?
Our finding of increased levels of S100B in patients with schizophrenia without an indication for significant glial (GFAP, MBP) or neuronal (NSE) damage may be interpreted as indirect evidence for increased active secretion of S100B during acute psychosis.
In adolescents, CSII use is associated with lower rates of retinopathy and peripheral nerve abnormality, suggesting an apparent benefit of CSII over MDI independent of glycemic control or SES.